Given that chemical AR degradation by PROTACs can provide advantages over simple inhibition by existing AR antagonists and that several PROTACs targeting AR have recently been introduced and shown therapeutic potential, we considered it worthwhile to develop novel AR-targeted PROTACs as a potential approach for the treatment of refractory prostate cancers. This evidence concerns the gene AR and Familial prostate cancer.